Protein Argonaute-1 (AGO1) Antibody
357.5€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Protein Argonaute-1 (AGO1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx122744
tested applications
ELISA, IHC
Description
Rabbit Polyclonal against the AGO1 protein.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Protein Argonaute-1 (AGO1) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/20000 - 1/80000, IHC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by antigen affinity column chromatography. |
| Size 1 | 100 µg |
| Size 2 | 1 mg |
| Form | Lyophilized |
| Tested Applications | ELISA, IHC |
| Buffer | Prior to lyophilization: 1% BSA and 0.02% NaN3. |
| Availability | Shipped within 7-15 working days. |
| Storage | Store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| NCBI Accession | NP_036331 |
| Alias | Q99,EIF2C,hAgo1,EIF2C1,GERP95,NEDLBAS |
| Background | Antibody anti-AGO1 |
| Status | RUO |
| Note | Concentration: Lyophilized form: Not applicable. After reconstitution: 1 mg/ml. - |
Descripción
AGO1 is a member of the Argonaute protein family, essential for the RNA-induced silencing complex (RISC), a key player in RNA interference (RNAi) and microRNA (miRNA)-mediated gene regulation. AGO1 primarily binds to miRNAs and facilitates the repression of target mRNA translation without significant endonucleolytic cleavage. Structurally, it contains conserved domains, including the PAZ domain, which binds the 3' end of small RNAs, and the PIWI domain, which has weak or no slicer activity in AGO1. AGO1 is expressed ubiquitously, with a role in post-transcriptional regulation in various biological processes, such as cell proliferation, differentiation, and stress responses. Dysregulation of AGO1 has been linked to diseases such as cancer and autoimmune disorders, where abnormal miRNA-mediated silencing affects critical pathways.
